Show simple item record
dc.description.abstractSince the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently, the World Health Organization (WHO) and the Pan American Health Organization (PAHO) recommend the use of corticosteroids, tocilizumab, baricitinib, and casirivimab e imdevimab (the latter in seronegative COVID-19 patients) and propose the use of sotrovimab, casirivimab/imdevimab, and molnupiravir in patients with non-severe illness who are at high risk for complications. Other potential therapeutic interventions are currently undergoing study or evaluation by WHO and PAHO. The interventions recommended at present and those that will be recommended at a later date pose challenges in terms of route of administration (e.g., oral or intravenous); efficacy, which depends on the viral variant; establishment of high-risk status (e.g., relative to vaccination status); cost; resources required to administer them; and other implementation-related aspects (e.g., distribution, drug safety monitoring, contraindications, interactions, etc.). To support decision-making for patient management, in this document PAHO presents considerations on the rational use of antivirals, monoclonal antibodies, and other interventions in light of the most current evidence, vaccination status, access, and the costs to countries of the Region.en_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 IGO*
dc.subjectEvidence-Based Medicineen_US
dc.subjectAccess to Essential Medicines and Health Technologiesen_US
dc.subjectPatient Care Managementen_US
dc.subjectLatin Americaen_US
dc.subjectCaribbean Regionen_US
dc.titleConsiderations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbeanen_US
dc.typeProcedures, manuals, guidelinesen_US
dc.rights.holderPan American Health Organizationen_US
dc.contributor.corporatenamePan American Health Organizationen_US
paho.publisher.countryUnited Statesen_US
paho.publisher.cityWashington, D.C.en_US
paho.contributor.departmentEvidence and Intelligence for Action in Health (EIH)en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 IGO
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO